![]() For more information, please visit and follow the company on Twitter and LinkedIn. The company is also using its platforms to develop other preclinical programs targeting multiple solid tumor indications. Using its TMAb platform, the company is developing SNS-101, a fully human antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively only within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. Sensei has designed two unique approaches to develop highly selective therapeutics – its TMAb™ (Tumor Microenvironment Activated biologics) platform, which disables checkpoints and other immuosuppressive signals in the tumor microenvironment to unleash existing T cells against tumors, and the ImmunoPhage™ platform, which trains new T cells to recognize and kill malignant cells. Sensei Biotherapeutics (NASDAQ: SNSE) is an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer. Portfolio managers and analysts who would like to request a meeting with management should contact their representative at the respective hosting firms. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer, today announced that Company management will participate in the following investor conferences in September 2022: Our website and mobile apps allow for easy sharing of all creative file types and provide an intuitive way to share, discuss, improve and approve ideas via a flexible user experience that adapts to. 23, 2022 (GLOBE NEWSWIRE) - Sensei Biotherapeutics, Inc. Hightail is designed to address the unique creative collaboration challenges faced by marketing professionals and the creative teams they work with.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |